Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 16 (6) , e1189-e1199
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
- Ministry of Science and ICT
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
This publication has 18 references indexed in Scilit:
- Mortality and Morbidity After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Population-Based StudyAnnals of Surgical Oncology, 2011
- Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell CarcinomaEuropean Urology, 2011
- EAU Guidelines on Renal Cell Carcinoma: The 2010 UpdateEuropean Urology, 2010
- Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?Cancer, 2010
- Contemporary Epidemiology of Renal Cell CancerThe Cancer Journal, 2008
- No improvement in renal cell carcinoma survival: A population-based study in the NetherlandsEuropean Journal of Cancer, 2008
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Five‐year survival after surgical treatment for kidney cancerCancer, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007